Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) healthcare and household cleaning products in North America, Australia, and internationally. It operates in three segments: North American OTC Healthcare, International OTC Healthcare, and Household Cleaning.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPersonal Products
SectorConsumer Discretionary
Phone914-524-6800
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$975.78 million
Profitability
Miscellaneous
Employees530
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable
Prestige Consumer Healthcare (NYSE:PBH) Frequently Asked Questions
What is Prestige Consumer Healthcare's stock symbol?
Prestige Consumer Healthcare trades on the New York Stock Exchange (NYSE) under the ticker symbol "PBH."
How were Prestige Consumer Healthcare's earnings last quarter?
Prestige Consumer Healthcare Inc (NYSE:PBH) posted its quarterly earnings data on Thursday, August, 1st. The company reported $0.65 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.01. The firm earned $232.15 million during the quarter, compared to analysts' expectations of $231.52 million. Prestige Consumer Healthcare had a negative net margin of 3.81% and a positive return on equity of 12.45%. Prestige Consumer Healthcare's revenue was down 8.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.68 EPS. View Prestige Consumer Healthcare's Earnings History.
When is Prestige Consumer Healthcare's next earnings date?
What guidance has Prestige Consumer Healthcare issued on next quarter's earnings?
Prestige Consumer Healthcare updated its FY20 earnings guidance on Thursday, August, 1st. The company provided earnings per share (EPS) guidance of $2.76-2.83 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.81. The company issued revenue guidance of $951-961 million, compared to the consensus revenue estimate of $954.73 million.
What price target have analysts set for PBH?
5 brokerages have issued 12 month price objectives for Prestige Consumer Healthcare's stock. Their forecasts range from $28.40 to $97.00. On average, they anticipate Prestige Consumer Healthcare's share price to reach $67.08 in the next twelve months. This suggests a possible upside of 105.3% from the stock's current price. View Analyst Price Targets for Prestige Consumer Healthcare.
What is the consensus analysts' recommendation for Prestige Consumer Healthcare?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prestige Consumer Healthcare in the last year. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Prestige Consumer Healthcare.
Has Prestige Consumer Healthcare been receiving favorable news coverage?
Press coverage about PBH stock has been trending positive this week, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Prestige Consumer Healthcare earned a media sentiment score of 2.5 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the company's share price in the next several days. View News Stories for Prestige Consumer Healthcare.
Who are some of Prestige Consumer Healthcare's key competitors?
Some companies that are related to Prestige Consumer Healthcare include Perrigo (PRGO), Dr.Reddy's Laboratories (RDY), Amarin (AMRN), Horizon Therapeutics (HZNP), Ascendis Pharma A/S (ASND), GW Pharmaceuticals PLC- (GWPH), ACADIA Pharmaceuticals (ACAD), Blueprint Medicines (BPMC), FibroGen (FGEN), Allakos (ALLK), United Therapeutics (UTHR), Mirati Therapeutics (MRTX), Alkermes (ALKS), Ultragenyx Pharmaceutical (RARE) and BridgeBio Pharma (BBIO).
What other stocks do shareholders of Prestige Consumer Healthcare own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Prestige Consumer Healthcare investors own include Gilead Sciences (GILD), GW Pharmaceuticals PLC- (GWPH), Cara Therapeutics (CARA), Dropcar (DCAR), Rigel Pharmaceuticals (RIGL), AbbVie (ABBV), Boeing (BA), Edwards Lifesciences (EW), Merck & Co., Inc. (MRK) and AT&T (T).
Who are Prestige Consumer Healthcare's key executives?
Prestige Consumer Healthcare's management team includes the folowing people:
- Mr. Ronald M. Lombardi, Chairman, Pres & CEO (Age 55)
- Ms. Christine Sacco, Chief Financial Officer (Age 43)
- Mr. William C. P'Pool, Sr. VP, Gen. Counsel & Corp. Sec. (Age 54)
- Mr. Timothy J. Connors, Exec. VP of Sales & Marketing (Age 52)
- Mr. Jeff Zerillo, Sr. VP of Operations
Who are Prestige Consumer Healthcare's major shareholders?
Prestige Consumer Healthcare's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (12.61%), Vanguard Group Inc. (9.57%), JPMorgan Chase & Co. (4.60%), Wells Fargo & Company MN (4.33%), Acadian Asset Management LLC (2.90%) and Royal Bank of Canada (2.46%). Company insiders that own Prestige Consumer Healthcare stock include Gary E Costley, Jean A Boyko, Natale S Ricciardi, Ronald M Lombardi, Timothy Connors and William P'pool. View Institutional Ownership Trends for Prestige Consumer Healthcare.
Which major investors are selling Prestige Consumer Healthcare stock?
PBH stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, JPMorgan Chase & Co., Janus Henderson Group PLC, Janus Henderson Group PLC, Dalton Greiner Hartman Maher & Co., Citadel Advisors LLC, Wells Fargo & Company MN and Invesco Ltd.. View Insider Buying and Selling for Prestige Consumer Healthcare.
Which major investors are buying Prestige Consumer Healthcare stock?
PBH stock was acquired by a variety of institutional investors in the last quarter, including Sterling Capital Management LLC, Nuveen Asset Management LLC, BlackRock Inc., Royal Bank of Canada, Acadian Asset Management LLC, Northern Trust Corp, Maverick Capital Ltd. and Russell Investments Group Ltd.. Company insiders that have bought Prestige Consumer Healthcare stock in the last two years include Gary E Costley, Natale S Ricciardi, Ronald M Lombardi and William P'pool. View Insider Buying and Selling for Prestige Consumer Healthcare.
How do I buy shares of Prestige Consumer Healthcare?
Shares of PBH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Prestige Consumer Healthcare's stock price today?
One share of PBH stock can currently be purchased for approximately $32.68.
How big of a company is Prestige Consumer Healthcare?
Prestige Consumer Healthcare has a market capitalization of $1.67 billion and generates $975.78 million in revenue each year. The company earns $-35,800,000.00 in net income (profit) each year or $2.78 on an earnings per share basis. Prestige Consumer Healthcare employs 530 workers across the globe.View Additional Information About Prestige Consumer Healthcare.
What is Prestige Consumer Healthcare's official website?
How can I contact Prestige Consumer Healthcare?
Prestige Consumer Healthcare's mailing address is 660 WHITE PLAINS ROAD SUITE 250, TARRYTOWN NY, 10591. The company can be reached via phone at 914-524-6800 or via email at [email protected]
MarketBeat Community Rating for Prestige Consumer Healthcare (NYSE PBH)
MarketBeat's community ratings are surveys of what our community members think about Prestige Consumer Healthcare and other stocks. Vote "Outperform" if you believe PBH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PBH will underperform the S&P 500 over the long term. You may vote once every thirty days.
